The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The pharmaceutical industry is undergoing a consolidation phase in order to combat price pressure, competition, and patent cliffs. Innovation is of vital importance for steady growth of key market players. They have been mainly dependent on a few blockbuster molecules. The patent expiry of blockbuster drugs is expected to pave way for generics. Due to difference in genetic composition of varied individuals, innovation is becoming more complex. This is influencing players offering complementary products and services to collaborate for new product development. Moreover, key market players are investing in consumer health products, with increasing consumer’s health awareness and emerging trend of self-medication. These trends are encouraging the key market players to enter the OTC market and leverage their brand equity among the doctors, chemists, and consumers.

Market Dynamics

The increasing prevalence of chronic diseases such as diabetes, cancer, cardiovascular disease, chronic kidney diseases, and others is expected to drive the growth of Oman pharmaceutical industry market over the forecast period. For instance, according to the World Health Organization 2018 report, in 2018, coronary heart disease deaths in Oman reached 2,904 or 28.23% of total deaths. The age adjusted death rate is 179.48 per 100,000 population, which ranks Oman at 45th position in the world in coronary heart disease patient population. Moreover, according to the World Health Organization (WHO), chronic kidney disease (CKD) is the sixth main cause of death in Oman, with a rate of 18.10 per 100,000 population (2.97% of total deaths) every year caused due to CKD in Oman. Similarly, Oman was ranked 51st among the top world countries in which CKD is a major cause of death.

Key features of the study

• This report provides in-depth analysis of the India & Oman pharmaceutical industry market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2026–2033), considering 2020 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the India & Oman pharmaceutical industry market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
• Key companies covered as a part of this study include Pfizer, Inc., Bristol Myers Squibb, Sanofi S.A., F. Hoffmann-La Roche AG, Bayer AG, Novartis International AG, Merck & Co., Inc., AbbVie, GlaxoSmithKline plc, Eli Lilly and Company, Zydus Cadila, Aurobindo Pharma Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin Ltd., Sun Pharmaceutical Industries Limited, Serum Institute of India Pvt. Ltd., Biocon Limited, Strides Pharma Science Limited, and Unichem Laboratories
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The India & Oman pharmaceutical industry market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the India & Oman pharmaceutical industry market

Market Segmentation

• By Drug Insights (Revenue, USD Mn, 2021 - 2033)
  • Generic
  • Patented (Branded)
• By Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Prescription Drugs
  • Over the Counter Drugs
• By Drug Class Insights (Revenue, USD Mn, 2021 - 2033)
  • Analgesics
  • Anesthetics
  • Antibacterials
  • Antidepressants
  • Corticosteroids
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Anticonvulsants
  • Antivirals
  • Anticoagulants
  • ACE inhibitors
  • Hormonal agents
  • Insulin
  • Contraceptives
  • Diuretics
  • Vaccines
  • Others
• By Application Insights (Revenue, USD Mn, 2021 - 2033)
  • Cardiovascular
    • Ischemic Heart Disease
    • Others
  • Hypertension
  • Musculoskeletal
  • Oncology
  • Anti-infective
  • Cirrhosis
  • Metabolic Disorder
    • Diabetes
    • Others
  • Weight Management
  • Central Nervous System
  • Genito-urinary
  • Kidney Disease
  • Gastrointestinal
  • Respiratory
  • Hematology
  • Dermatology
  • Ophthalmology
  • Others (Nutraceutical, Dentals, and Gynecology)
• By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region Insights (Revenue, USD Mn, 2021 - 2033)
  • India
  • Oman
• Key Players in the India and Oman Pharmaceutical Industry Market
  • Pfizer, Inc.
  • Bristol Myers Squibb
  • Sanofi S.A.
  • Hoffmann-La Roche AG
  • Bayer AG
  • Novartis International AG
  • Merck & Co., Inc.
  • AbbVie
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Zydus Cadila
  • Aurobindo Pharma Ltd.
  • Cipla Ltd.
  • Reddy's Laboratories Ltd.
  • Lupin Ltd.
  • Sun Pharmaceutical Industries Limited
  • Serum Institute of India Pvt. Ltd.
  • Biocon Limited
  • Strides Pharma Science Limited
  • Unichem Laboratories